Aethlon Medical Corp (AEMD) - מזומנים למניה אחת

Is it worth investing in the developer of unique filtration systems for pathogens and cancer cells in the blood? The current cash per share provides the answer, and 4.04 captures the current value of this indicator. Aethlon Medical (AEMD) revenues will be based on the implementation of Hemopurifier to combat viruses. Currently, the company seeks to occupy a medical niche before the arrival of corporate behemoths.
פילוחי מדדים מקיפים ואנליטיקה עבור Aethlon Medical Corp (AEMD)

Aethlon Medical (AEMD) has optimized costs by outsourcing the production of filtration cartridges while maintaining control over its IP. This indicator determines the amount of liquid assets per share, reflecting the issuer's actual cash cushion. An increase in this metric to 4.04 indicates a strengthening balance sheet, although excess cash may reduce overall profitability. Investors should view this reserve as a hedge against volatility. By analyzing the change in cash per share, one can determine the company's stability independent of market hype.